URGN: מכפיל מחיר לרווח לצמיחה urogen.com
UroGen Pharma Ltd. (URGN) focuses on urological oncology, mitigating narrow portfolio risks through the success of its first drug. The growth company undervaluation metric reflects the asset's value dynamics, where the current mark is 0.00. A unique drug delivery method provides a competitive edge, enabling the company to maintain pricing power. Meanwhile, operational stability is based on the utilization of external contract manufacturing organizations in the US and Israel.
UroGen Pharma Ltd. (URGN) - פילוחי מדדים ודוחות פיננסיים
This indicator compares the market value of a share with the growth rate of earnings per share, identifying an undervalued asset when the value falls below one. For UroGen Pharma Ltd. (URGN), which is developing innovative gel-based cancer therapies, the PEG ratio allows for an assessment of how much the current price reflects the long-term commercialization potential of these technologies.
